CAR T-Cell therapy Market Expected to Reach USD 6.1 Billion by 2031 | Current Trends and Industry Analysis

Car t-cell therapy market was valued at $1.7 billion in 2021, and is estimated to reach $6.1 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031. Chimeric antigen receptor (CAR) T-cell therapy treats certain cancer by turning T-cells into more efficient cancer-fighting cells. CAR T-cell therapy is a novel targeted approach, which involves genetic engineering of T-cells to specifically target the receptors on cancer cells.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
The key players operating in the CAR T-cell therapy industry are Autolus, Bluebird Bio-Inc., Bristol-Myers Squibb, Caribou Biosciences Inc., Cartesian Therapeutics, Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Merck & Co. Inc., Miltenyi Biotech, Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/17358

𝗖𝗼𝘃𝗶𝗱-𝟭𝟵 𝗦𝗰𝗲𝗻𝗮𝗿𝗶𝗼:
The COVID-19 outbreak is anticipated to have a negative impact on the market, as huge number of medical college and hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. The COVID-19 pandemic had a negative impact on the market because priority is given to COVID-19 patient for treatment. Discovery and development of CAR T-cell therapy medicine slowed down during the pandemic but did not stop. The significant reduction in clinical trials due to strict government guidelines against COVID-19, resists the growth of CAR T-cell therapy market size. Decline in people transit, closing of borders, and confinement of the population impacted the supply chains of these life-saving medical products in the CAR T-cell therapy market share. Nonessential surgical procedures took a potential backlog and home setting care was preferred, owing to rapidly rising COVID-19 cases, as only elective emergency surgeries were performed.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/17358

By drug type, the axicabtagene ciloleucel segment was the highest revenue contributor to the market owing to increase in adoption of (Yescarta) axicabtagene ciloleucel for treatment of relapsed or refractory large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The brexucabtagene autoleucel segment is expected to witness highest CAGR during the forecast period, owing to rise in approval of CAR T-cell therapies in different countries for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

On the basis of indication, the lymphoma segment generated maximum revenue in 2021 owing to higher number of approved CAR T-cell therapeutics for treatment of different form of lymphoma with large number of target population. The acute lymphocytic leukemia segment is expected to witness highest CAGR during the forecast period, owing to increase in awareness of CAR T-cell therapeutics for treatment of ALL and expected launch of these drug for treatment of ALL.

On the basis of end user, the hospitals segment was the highest revenue contributor to the market in 2021, owing to factors, such as well-equipped operation theatre, higher buying power, and rise in patient admission. The cancer treatment centers segment is expected to witness highest CAGR during the forecast period, owing to availability of a wide range of choice of treatment and increase in number of cancer centers in some developing nations.

Region-wise, in CAR-T cell therapy industry, North America generated higher revenue in 2021, owing to strong presence of key players and availability of approved therapeutics with higher adoption of CAR T-cell therapies. Asia-Pacific is expected to witness highest CAGR during the forecast period owing to rise in awareness regarding CAR T-cell therapy, expected launch of CART drugs, and rise in the number of target population.

𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘

• By drug type, the axicabtagene ciloleucel segment held the largest share in the CAR T-cell therapy market in 2021.
• By indication, the lymphoma segment held the largest share in the CAR T-cell therapy market in 2021.
• By end user, the cancer centers segment is expected to show the fastest market growth during the forecast period.
• Region-wise, North America held the largest market share in 2021.

𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:

Behavioral Health Market -- https://www.alliedmarketresearch.com/behavioral-health-market-A17079

Nucleic Acid Therapeutics Market -- https://www.alliedmarketresearch.com/nucleic-acid-therapeutics-market-A17089

Contact:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.